

Dishman Carbogen Amcis

27 December 2019

Reuters: DSHM.NS; Bloomberg: DCAL IN

Management Call Update

We hosted a concall with Dishman Carbogen Amcis Ltd management with institutional investors considering the recent steep correction in stock price post week long IT search operations conducted at various company premises. Overall the company does not anticipate a materially adverse outcome from the IT investigation and reinstated its commitment to highest standards of corporate governance and ethics. From a business perspective they also reinstated their guidance for 8-10% revenue growth and EBITDA margins around 27%.

IT search operations were done very courteously and the company extended full cooperation to the IT officials. The data needs of the IT department could be immediately addressed as they have made good progress towards complete automation of accounts. The search operations were unanticipated as there was no prior tax demand notice that was received. Transfer pricing, goodwill amortization were among the few aspects explored during the search operations. With regard to transfer pricing, the company has indicated in most geographies they operate in are at more or less the same tax rate. Like in India they are under MAT (20%), and likewise the tax rate in UK, Switzerland, and Nederland are also 19%, 20%, and 25% respectively. The IT search did not extend to other promoter group entities. It lasted almost a week long as the officials had follow up requirements of data, which was furnished to their satisfactions.

The search operations had no impact on the routine business operations and customer shipments were released on schedule. Revenue growth guidance of 8-10% for FY-20 has been maintained. EBITDA margins should be in the range of 27%. EBITDA margin expansion will be gradual and they expect a 300bps expansion over next 3-5 years.

Fundamentally, company continues to have a robust standing in the CRAMS space. The custom synthesis pipeline has around 500 molecules, which is larger than most competing players at the global level. The Phase 3 pipeline is also very strong with 18 molecules, of which about 4 are in validation stages, which ensures the company can continue to build its commercial manufacturing revenue stream in the near to medium term. Within the Phase 3 pipeline there are two Anti body Drug Conjugates as well which requires niche development skills and DCAL has been able to build early capabilities. Orders for niraparib, one of their key molecules in commercial manufacturing has stalled for a while, as there is inventory buildup. Approval for niraparib in new indications should bring back demand. With regard to Vitamin D business, the company continues to build new avenues of growth by investing in capacities, improving process to lower costs and forward integrating to formulations.

Other Business Updates

Moving to New Tax regime should reduce tax outgo: Company would be adopting the new tax regimen from FY21 onwards and this should lower their tax outflow. The reported tax rate would stand at 25%, but the cash outgo would be nil.

Capacity Utilization: The gross block currently on the books of the Company is Rs20,000mn and the Company has Fixed Asset turnover of around 0.9. The capacity utilization for the sites is Switzerland – 85%, Bavla -65%, China – 25%, Netherlands- 60% and Manchester – 75-80%.

Debt: The Company has net debt of Rs8,000mn which is on a higher side due to front ended CapEx. The Company will continue to lower debt. In first six months of FY20 debt was lowered by \$8mn

Y/E March (Rsmn)	FY18	FY19	FY20E	FY21E	FY22E
Net sales	16,948	20,586	22,302	24,419	26,971
EBITDA	4,454	5,519	5,649	6,101	6,660
Net profit	1,546	2,103	1,938	2,179	2,541
EPS (Rs)	9.6	13.0	12.0	13.5	15.7
EPS growth (%)	6.3	36.1	(7.8)	12.4	16.6
Cash EPS (Rs)	13.4	16.9	15.8	17.3	19.6
Cash EPS growth (%)	4.4	25.8	(6.1)	9.4	12.9
EBITDA margin (%)	26.3	26.8	25.3	25.0	24.7
PER (x)	13.6	6.1	6.6	5.9	5.0
P/BV (x)	0.4	0.2	0.2	0.2	0.2
EV/EBITDA (x)	6.4	3.7	3.2	2.7	2.2
RoCE (%)	4.1	5.4	4.6	5.1	5.7
RoE (%)	3.0	3.9	3.5	3.8	4.2

Source: Company, Nirmal Bang Institutional Equities Research

BUY

Sector: Pharmaceuticals

CMP: Rs79

Target Price: Rs185

Upside: 133%

Vishal Manchanda

 Research Analyst
 vishal.manchanda@nirmalbang.com
 +91-97374-37148

Gaurang Sakare

 Research Associate
 gaurang.sakare@nirmalbang.com
 +91-22 6273 8093

Key Data

Current Shares O/S (mn)	161.4
Mkt Cap (Rsbn/US\$mn)	12.8/241.5
52 Wk H / L (Rs)	258/71
Daily Vol. (3M NSE Avg.)	962,234

Price Performance (%)

	1 M	6 M	1 Yr
Dishman Carbogen	(41.6)	(65.0)	(65.4)
Nifty Index	0.2	2.4	12.5

Source: Bloomberg

Financials

Exhibit 1: Income statement

Y/E March (Rsmn)	FY18	FY19	FY20E	FY21E	FY22E
Net sales	16,948	20,586	22,302	24,419	26,971
% growth	(1.1)	21.5	8.3	9.5	10.5
Raw material costs	3,369	4,038	4,468	4,830	5,356
Staff costs	6,254	7,146	8,147	9,287	10,588
Other expenditure	2,871	3,883	4,038	4,200	4,368
Total expenditure	12,494	15,067	16,653	18,318	20,311
EBITDA	4,454	5,519	5,649	6,101	6,660
% growth	(1.8)	23.9	2.4	8.0	9.2
EBITDA margin (%)	26.3	26.8	25.3	25.0	24.7
Other income	457	538	484	577	673
Interest costs	488	566	640	700	700
Gross profit	13,579	16,548	17,834	19,588	21,615
% growth	(1.9)	21.9	7.8	9.8	10.3
Depreciation	2,114	2,404	2,771	2,917	3,064
Profit before tax	2,308	3,088	2,722	3,061	3,569
% growth	6.4	33.8	(11.8)	12.4	16.6
Tax	762	985	784	881	1,028
Effective tax rate (%)	33.0	31.9	28.8	28.8	28.8
Net profit	1,546	2,103	1,938	2,179	2,541
% growth	6.3	36.1	(7.8)	12.4	16.6
EPS (Rs)	9.6	13.0	12.0	13.5	15.7
% growth	6.3	36.1	(7.8)	12.4	16.6
Cash EPS	13.4	16.9	15.8	17.3	19.6
% growth	4.4	25.8	(6.1)	9.4	12.9

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 3: Balance sheet

Y/E March (Rsmn)	FY18	FY19	FY20E	FY21E	FY22E
Net worth	51,073	53,791	55,710	57,870	60,391
Net deferred tax liabilities	1,321	1,404	1,404	1,404	1,404
Short-term loans	3,933	5,201	4,837	4,605	4,370
Long-term loans	5,250	3,624	3,124	2,624	2,124
Other non-current liabilities	2,343	2,483	2,483	2,483	2,483
Liabilities	63,921	66,503	67,557	68,985	70,772
Net block	15,033	15,330	13,878	14,095	14,166
Capital WIP	1,190	1,433	1,433	1,433	1,433
Intangible assets and goodwill	35,891	35,913	35,028	34,143	33,259
Other non-current assets	4,189	5,073	5,073	5,073	5,073
Inventories	4,846	5,486	6,071	6,563	7,284
Debtors	4,444	4,453	6,022	6,593	7,282
Cash	691	957	2,208	3,344	4,702
Loans and advances	755	42	45	49	55
Other current assets	4,726	4,598	4,598	4,598	4,598
Total current assets	15,462	15,536	18,944	21,148	23,920
Creditors	1,859	1,946	2,145	2,319	2,571
Other current liabilities	5,985	4,837	4,653	4,589	4,508
Total current liabilities	7,844	6,782	6,798	6,907	7,079
Net current assets	7,617	8,754	12,146	14,241	16,841
Total assets	63,921	66,503	67,557	68,985	70,772

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 2: Cash flow

Y/E March (Rsmn)	FY18	FY19	FY20E	FY21E	FY22E
PBT	2,308	3,088	2,722	3,061	3,569
(Inc./)dec in working capital	(1,434)	(870)	(2,140)	(959)	(1,243)
Cash flow from operations	874	2,218	582	2,101	2,326
Other income	(457)	(538)	(484)	(577)	(673)
Finance costs	488	566	640	700	700
Depreciation	2,114	2,404	2,771	2,917	3,064
Tax paid	327	82	0	0	0
Net cash from operations	(762)	(985)	(784)	(881)	(1,028)
Capital expenditure	2,585	3,747	2,725	4,260	4,389
Net cash after capex	(4,427)	(2,966)	(434)	(2,250)	(2,250)
Other investing activities	(1,842)	781	2,291	2,010	2,139
Cash from financial activities	(53)	(345)	484	577	673
Opening cash balance	1,712	(169)	(1,523)	(1,452)	(1,454)
Change in cash balance	874	691	957	2,208	3,344
Closing cash balance	(183)	266	1,252	1,136	1,358

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 4: Key ratios


Y/E March	FY18	FY19	FY20E	FY21E	FY22E
Profitability & return ratios					
EBITDA margin (%)	26.5	26.3	26.8	25.3	25.0
EBIT margin (%)	12.7	13.6	15.0	12.2	12.5
Net profit margin (%)	8.5	9.1	10.2	8.7	8.9
RoE (%)	3.0	3.0	3.9	3.5	3.8
RoCE (%)	4.1	4.1	5.4	4.6	5.1
Working capital & liquidity ratios					
Receivables (days)	61	96	79	99	99
Inventory (days)	473	525	496	496	496
Payables (days)	95	201	176	175	175
Current ratio (x)	2.0	2.0	2.3	2.8	3.1
Quick ratio (x)	1.3	1.4	1.5	1.9	2.1
Valuation ratios					
EV/sales (x)	1.7	1.7	1.0	0.8	0.7
EV/EBITDA (x)	6.3	6.4	3.7	3.2	2.7
P/E (x)	14.4	13.6	6.1	6.6	5.9
P/BV (x)	0.4	0.4	0.2	0.2	0.2

Source: Company, Nirmal Bang Institutional Equities Research

Rating track

Date	Rating	Market price (Rs)	Target price (Rs)
18 May 2017	Buy	305	387
2 May 2017	Buy	311	380
13 November 2017	Buy	306	410
29 January 2018	Accumulate	383	418
18 May 2018	Buy	340	404
27 July 2018	Buy	278	404
5 November 2018	Buy	229	429
25 January 2019	Buy	229	429
5 April 2019	Buy	226	446
17 May 2019	Buy	209	425
16 August 2019	Buy	186	344
23 September 2019	Buy	185	369
25 October 2019	Buy	130	185
27 December 2019	Buy	79	185

Rating track graph



DISCLOSURES

This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as “NBEPL”) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments.

NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company.

Analyst Certification: I, Vishal Manchanda, research analyst and Gaurang Sakare, Research Associate the author of this report, hereby certify that the views expressed in this research report accurately reflects my personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst is principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Disclaimer

Stock Ratings Absolute Returns

BUY > 15%

ACCUMULATE -5% to 15%

SELL < -5%

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader.

This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Copyright of this document vests exclusively with NBEPL.

Our reports are also available on our website www.nirmalbang.com

Access all our reports on Bloomberg, Thomson Reuters and Factset.

Team Details:			
Name		Email Id	Direct Line
Rahul Arora	CEO	rahul.arora@nirmalbang.com	-
Girish Pai	Head of Research	girish.pai@nirmalbang.com	+91 22 6273 8017 / 18
Dealing			
Ravi Jagtiani	Dealing Desk	ravi.jagtiani@nirmalbang.com	+91 22 6273 8230, +91 22 6636 8833
Pradeep Kasat	Dealing Desk	pradeep.kasat@nirmalbang.com	+91 22 6273 8100/8101, +91 22 6636 8831
Michael Pillai	Dealing Desk	michael.pillai@nirmalbang.com	+91 22 6273 8102/8103, +91 22 6636 8830

Nirmal Bang Equities Pvt. Ltd.

Correspondence Address

B-2, 301/302, Marathon Innova,
 Nr. Peninsula Corporate Park,
 Lower Parel (W), Mumbai-400013.

Board No. : 91 22 6273 8000/1; Fax. : 022 6273 8010